Standex (SXI) has acquired Michigan-based Custom Biogenic Systems for approximately $6.2M in cash. The transaction is being financed from Standex’s existing cash balance. In its first year of ownership, the company expects the acquisition to be accretive to its earnings. CBS will be reported as part of Standex’s Scientific business segment. Founded in 1987, Custom Biogenic Systems is a leader in the design and manufacturing of laboratory products and supplies. CBS specializes in the development and manufacturing of cryogenic equipment to the pharmaceutical and biobank end markets within life sciences. In calendar year 2024, Custom Biogenic Systems estimates revenues of approximately $15M.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXI:
- Clearfield elects Kate Kelly, Ademir Sarcevic to board of directors
- Barrington says Standex Q1/25 highlights accretive Amran/Narayan Group deal
- Standex price target raised to $250 from $210 at Benchmark
- Standex International’s Q1 Fiscal 2025 Performance and Outlook
- Standex International Expands in Electrical Grid Market